
COMMISSION REGULATION (EU) 2015/1221 of 24 July 2015 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress (Text with EEA relevance) 

THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, and in particular Article 37(5) thereof,
Whereas:

(1) Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC.

(2) Proposals for new or updated harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA, as well as on the comments received from the parties concerned, it is appropriate to introduce or update harmonised classification and labelling of certain substances by amending Annex VI to that Regulation.

(3) With regard to the substance nitric acid … % (EC number: 231-714-2), new scientific data has been made available for the hazard class ‘acute toxicity’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has issued an opinion on the new information, while all other classes covered by the earlier opinion should be included.

(4) With regard to the substance phenol, dodecyl-, branched (EC number: 310-154-3), the RAC is in the process of adopting a new opinion for the specific concentration limits to be applied to the hazard class ‘toxic for reproduction’. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until that opinion is finalised.

(5) Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. In addition, a certain period of time will be necessary to allow suppliers to comply with the registration obligations resulting from the new harmonised classifications for substances classified as carcinogenic, mutagenic or toxic to reproduction, categories 1A and 1B (Table 3.1) and categories 1 and 2 (Table 3.2), or as very toxic to aquatic organisms which may cause long term effects in the aquatic environment, in particular with those set out in Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council.

(6) In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

(7) The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006,
HAS ADOPTED THIS REGULATION:

Article 1 
Annex VI to Regulation (EC) No 1272/2008 is amended in accordance with the Annex to this Regulation.
Article 2 
By way of derogation from Article 3(2), the harmonised classifications set out in Annex to this Regulation may be applied before the date referred to in Article 3(2).
Article 3 

1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
2. Article 1 shall apply in respect of substances and mixtures from 1 January 2017.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 24 July 2015.
For the Commission
The President
Jean-Claude JUNCKER
ANNEX

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

((1)) Table 3.1 is amended as follows:

((a)) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
007-004-00-1 nitric acid … % 231-714-2 7697-37-2 Ox. Liq. 2Skin Corr. 1A H272H314 GHS03GHS05Dgr H272H314 EUH071 Skin Corr. 1A; H314: C ≥ 20 %Skin Corr. 1B; H314: 5 % ≤ C < 20 %Ox. Liq. 2; H272: C ≥ 99 %Ox. Liq. 3; H272: 99 % > C ≥ 65 % B
015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 Water-react. 1Acute Tox. 2Acute Tox. 3Acute Tox. 1Eye Dam. 1Aquatic Acute 1 H260H300H311H330H318H400 GHS02GHS06GHS05GHS09Dgr H260H300H311H330H318H400 EUH029EUH032 M = 100 
031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. 1BCarc. 1BSTOT RE 1 H360FH350H372 (respiratory and haematopoietic systems) GHS08Dgr H360FH350H372 (respiratory and haematopoietic systems)   
050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. 1BAcute Tox. 3Acute Tox. 4*STOT RE 1Skin Irrit. 2Eye Irrit. 2Aquatic Acute 1Aquatic Chronic 1 H360FDH301H312H372**H315H319H400H410 GHS08GHS06GHS09Dgr H360FDH301H312H372**H315H319H410  *STOT RE 1; H372: C ≥ 1 %STOT RE 2; H373: 0,25 % ≤ C < 1 %Skin Irrit. 2; H315:C ≥ 1 %Eye Irrit. 2; H319:C ≥ 1 %M = 10 A1
603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 Flam. Liq. 2Carc. 2Acute Tox. 4*Acute Tox. 4*Acute Tox. 4*STOT SE 3Skin Irrit. 2Eye Irrit. 2 H225H351H302H312H332H335H315H319 GHS02GHS08GHS07Dgr H225H351H302H312H332H335H315H319   
603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. 2Acute Tox. 4Aquatic Acute 1Aquatic Chronic 1 H361d***H302H400H410 GHS08GHS07GHS09Wng H361d***H302H410  M = 1M = 10 
606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone — 141112-29-0 Repr. 2Aquatic Acute 1Aquatic Chronic 1 H361d***H400H410 GHS08GHS09Wng H361d***H410  M = 10M = 100 
607-197-00-8 nonanoic acid 203-931-2 112-05-0 Skin Irrit. 2Eye Irrit. 2Aquatic Chronic 3 H315H319H412 GHS07Wng H315H319H412   
613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 252-615-0 35554-44-0 Carc. 2Acute Tox. 3Acute Tox. 4Eye Dam. 1Aquatic Chronic 1 H351H301H332H318H410 GHS08GHS06GHS05GHS09Dgr H351H301H332H318H410  M = 10 
613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. 2STOT RE 2Skin Corr. 1CSkin Sens. 1AAquatic Acute 1Aquatic Chronic 1 H361dH373 (liver)H314H317H400H410 GHS08GHS05GHS07GHS09Dgr H361dH373 (liver)H314H317H410 EUH071 M = 1M = 1 
613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. 2Acute Tox. 4Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H351H302H317H400H410 GHS08GHS07GHS09Wng H351H302H317H410  M = 1M = 1 
613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 Acute Tox. 3Acute Tox. 3Aquatic Acute 1Aquatic Chronic 1 H331H301H400H410 GHS06GHS09Dgr H331H301H410  M = 1 000M = 1 000 
((b)) the following entries are inserted in accordance with the order of the entries set out in Table 3.1:

Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes
Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Eye Irrit. 2 H319 GSH07Wng H319   
604-092-00-9 phenol, dodecyl-, branched [1];phenol, 2-dodecyl-, branched;phenol, 3-dodecyl-, branched;phenol, 4-dodecyl-, branched;phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1] 121158-58-5 [1]74499-35-7 [2] Skin Corr. 1CAquatic Acute 1Aquatic Chronic 1 H314H400H410 GHS05GHS09Dgr H314H410  M = 10M = 10 
606-148-00-8 carvone (ISO);2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1]218-827-2 [2]229-352-5 [3] 99-49-0 [1]2244-16-8 [2]6485-40-1 [3] Skin Sens. 1 H317 GHS07Wng H317   
606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione — 335104-84-2 Repr. 2STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H361dH373 (eyes, kidneys, liver)H317H400H410 GHS08GHS07GHS09Wng H361dH373 (eyes, kidneys, liver)H317H410  M = 100M = 10 
607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H373 (kidneys)H317H400H410 GHS08GHS07GHS09Wng H373 (kidneys)H317H410  M = 1M = 1 
607-708-00-4 octanoic acid 204-677-5 124-07-2 Skin Corr. 1CAquatic Chronic 3 H314H412 GHS05Dgr H314H412   
607-709-00-X decanoic acid 206-376-4 334-48-5 Skin Irrit. 2Eye Irrit. 2Aquatic Chronic 3 H315H319H412 GHS07Wng H315H319H412   
607-710-00-5 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. 1B H360FD GHS08Dgr H360FD   
607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. 2STOT SE 3Eye Irrit. 2Skin Sens. 1AAquatic Acute 1Aquatic Chronic 1 H361fdH335H319H317H400H410 GHS08GHS07GHS09Wng H361fdH335H319H317H410  M = 1M = 1 
607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. 2STOT RE 2Skin Corr. 1CSkin Sens. 1AAquatic Chronic 1 H361dH373 (liver)H314H317H410 GHS08GHS05GHS07GHS09Dgr H361dH373 (liver)H314H317H410 EUH071 M = 1 
607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 Acute Tox. 3Acute Tox. 2Skin Sens. 1BAquatic Acute 1Aquatic Chronic 1 H301H330H317H400H410 GHS06 GHS09Dgr H301H330H317H410  M = 100M = 1 000 
607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. 2Aquatic Acute 1Aquatic Chronic 1 H351H400H410 GHS08GHS09Wng H351H410  M = 100M = 10 
607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H373H317H400H410 GHS08GHS07GHS09Wng H373H317H410  M = 1M = 1 
613-319-00-0 imidazole 206-019-2 288-32-4 Repr. 1BAcute Tox. 4Skin Corr. 1C H360DH302H314 GHS08GHS07GHS05Dgr H360DH302H314   
613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. 2Aquatic Acute 1Aquatic Chronic 1 H351H400H410 GHS08GHS09Wng H351H410  M = 10M = 10 
616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 Aquatic Acute 1Aquatic Chronic 1 H400H410 GHS09Wng H410  M = 1M = 1 
616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. 2STOT RE 2Aquatic Acute 1Aquatic Chronic 1 H351H373 (eyes, kidneys)H400H410 GHS08GHS09Wng H351H373 (eyes, kidneys)H410  M = 1 000M = 100 
616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Acute Tox. 4Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 H302H317H400H410 GHS07GHS09Wng H302H317H410  M = 10M = 10 
616-216-00-9 flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Acute Tox. 4 H302 GHS07Wng H302   
616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Acute Tox. 4Aquatic Acute 1Aquatic Chronic 1 H302H400H410 GHS07GHS09Wng H302H410  M = 1M = 1 
((2)) Table 3.2 is amended as follows:

((a)) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes
007-004-00-1 nitric acid … % 231-714-2 7697-37-2 O; R8C; R35 O; CR: 8-35S: (1/2-)26-28- 36/37/39-45-63 O; R8: C ≥ 65 %C; R35: C ≥ 20 %C; R34: 5 % ≤ C < 20 % B
015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 F; R15/29T+; R26/28Xn; R21R32Xi; R38-41N; R50 F; T+; NR: 15/29-21-26/28-32-38-41-50S:(1/2-)26-28-30-36/37/39-43-45-60-61 N; R50: C ≥ 0,25 % 
031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. Cat. 2; R60Carc. Cat. 2; R45T; R48/23 TR: 45-48/23-60S: 45-53  E
050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. Cat. 2; R60-61T; R25-48/23/25Xn; R21Xi; R36/38N; R50-53 T; NR: 21-25-36/38-48/23/25-50/53-60-61S: 45-53-60-61 T; R25: C ≥ 2,5 %Xn; R22: 0,25 % ≤ C < 2,5 %Xn: R21: C ≥ 1 %T; R48/23/25: C ≥ 1 %Xn; R48/20/22: 0,25 % ≤ C < 1 %Xi; R36/38: C ≥ 1 %N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % A1
603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 F; R11Carc. Cat. 3; R40Xn; R20/21/22Xi; R36/37/38 F; XnR: 11-20/21/22-36/37/38-40-S: (2-)9-16-29-36/37-46  
603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. Cat. 3; R63Xn; R22N; R50-53 Xn; NR: 22-50/53-63S: (2-)22-36/37-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C <25 %R52-53: 0,25 % ≤ C < 2,5 % 
606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone — 141112-29-0 Repr. Cat. 3; R63N; R50-53 Xn; NR: 50/53-63S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
607-197-00-8 nonanoic acid 203-931-2 112-05-0 Xi; R36/38N; R51-53 Xi; NR: 36/38-51/53S: (2-)46-61  
613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 252-615-0 35554-44-0 Carc. Cat. 3; R40Xn; R20/22Xi; R41N; R51-53 Xn; NR: 20/22-40-41-51/53S: (2-)26-36/37/39-46-61  
613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. Cat. 3; R63C; R34R43N; R50-53 C; NR: 34-43-50/53-63S: (1/2-)26-28-36/37/39-45-60-61 C; R34: C ≥ 10 %Xi; R36/37/38: 5 % ≤ C < 10 %N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. Cat. 3; R40Xn; R22R43N; R50-53 Xn; NR: 22-40-43-50/53S: (2-)36/37-46-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 T; R23/25N; R50-53 T; NR: 23/25-50/53S: (1/2-)36/37-45-60-61 N; R50-53: C ≥ 0,025 %N; R51-53: 0,0025 % ≤ C < 0,025 %R52-53: 0,00025 % ≤ C < 0,0025 % 
((b)) the following entries are inserted in accordance with the order of the entries set out in Table 3.2:

Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes
019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Xi; R36 XiR: 36S: (2-)25-46  
604-092-00-9 phenol, dodecyl-, branched [1];phenol, 2-dodecyl-, branched;phenol, 3-dodecyl-, branched;phenol, 4-dodecyl-, branched;phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1]-[2] 121158-58-5 [1]74499-35-7 [2] C; R34N; R50-53 C; NR: 34-50/53S: (1/2-)26-36/37/39-45-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
606-148-00-8 carvone (ISO);2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1]218-827-2 [2]229-352-5 [3] 99-49-0 [1]2244-16-8 [2]6485-40-1 [3] R43 XiR: 43S: (2-)24-37  
606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione  335104-84-2 Repr. Cat. 3; R63Xn; R48/22R43N; R50-53 Xn; NR: 43-48/22-50/53-63S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,25 %N; R51-53: 0,025 % ≤ C < 0,25 %R52-53: 0,0025 % ≤ C < 0,025 % 
607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 Xn; R48/22R43N; R50-53 Xn; NR: 43-48/22-50/53S: (2-)24-37-46-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
607-708-00-4 octanoic acid 204-677-5 124-07-2 C; R34N; R51-53 C; NR: 34-51/53S: (1/2-)26-36/37/39-45-61  
607-709-00-X decanoic acid 206-376-4 334-48-5 Xi; R36/38N; R51-53 Xi; NR: 36/38-51/53S: (2-)25-46-61  
607-710-00-5 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. Cat. 2; R60-61 TR: 60-61S: 53-45  
607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. Cat. 3; R62-63Xi; R36/37R43N; R50-53 Xn; NR: 36/37-43-50/53-62-63S: (2-)36/37-60-61 Xi; R43: C ≥ 0,1 %N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. Cat. 3; R63C; R34R43N; R51-53 C; NR: 34-43-51/53-63S: (1/2-)26-28-36/37/39-45-61 C; R34: C ≥ 10 %Xi: R36/37/38: 5 % ≤ C < 10 % 
607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 T+; R26Xn; R22R43N; R50-53 T+; NR: 22-26-43-50/53S: (1/2-)28-36/37-45-60-61-63 N; R50-53: C ≥ 0,25 %N; R51-53: 0,025 % ≤ C < 0,25 %R52-53: 0,0025 % ≤ C < 0,025 % 
607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. Cat. 3; R40N; R50-53 Xn; NR: 40-50/53S: (2-)36/37-60-61 N; R50-53: C ≥ 0,25 %N; R51-53: 0,025 % ≤ C < 0,25 %R52-53: 0,0025 % ≤ C < 0,025 % 
607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 R43N; R50-53 Xi; NR: 43-50/53S: (2-)24-37-60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
613-319-00-0 imidazole 206-019-2 288-32-4 Repr. Cat 2; R61Xn; R22C; R34 T; CR: 22-34-61S: 53-45  
613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. Cat. 3; R40N; R50-53 Xn; NR: 40-50/53S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 N; R50-53 NR: 50/53S: 60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C <25 %R52-53: 0,25 % ≤ C < 2,5 % 
616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. Cat. 3; R40Xn; R48/22N; R50-53 Xn; NR: 40-48/22-50/53S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,025 %N; R51-53: 0,0025 % ≤ C < 0,025 %R52/53: 0,00025 % ≤ C < 0,0025 % 
616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Xn; R22R43N; R50-53 Xn; NR: 22-43-50/53S: (2-)24-37-60-61 N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % 
616-216-00-9 flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Xn; R22 XnR: 22S: (2-)46  
616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Xn; R22N; R50-53 Xn; NR: 22-50/53S: (2-)60-61 N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % 
